Sunitinib-containing carborane pharmacophore with the ability to inhibit tyrosine kinases receptors FLT3, KIT and PDGFR-β, exhibits powerful in vivo anti-glioblastoma activity

Malignant gliomas are the most common malignant and aggressive primary brain tumors in adults, the prognosis being—especially for glioblastomas—extremely poor. There are no effective treatments yet. However, tyrosine kinase receptor (TKR) inhibitors and boron neutron capture therapy (BNCT), together...

Descripció completa

Dades bibliogràfiques

Autor principal:	Alamón, Catalina (author)
Altres autors:	Dávila Saralegui, Belén (author), García Melián, María Fernanda (author), Sánchez, Carina (author), Kovacs, Mariángeles (author), Trias, Emiliano (author), Barbeito, Luis (author), Gabay, Martín (author), Zeineh, Nidal (author), Gavish, Moshe (author), Teixidor, Francesc (author), Viñas, Clara (author), Couto, Marcos (author), Cerecetto, Hugo (author)
Format:	article
Idioma:	anglès
Publicat:	2020
Matèries:	Carborane FLT3 Sub-G1 arrest Anti-tumor activity
Accés en línia:	https://hdl.handle.net/20.500.12008/31990
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!